Outcomes of COMBO therapy for severe mitral regurgitation compared with transcatheter edge-to-edge repair.

Authors:
Yokoyama H; Ruf TF; Gößler TAM; Geyer M; Zirbs J and 3 more

Journal:
Front Cardiovasc Med

Publication Year: 2024

DOI:
10.3389/fcvm.2024.1223588

PMCID:
PMC10925764

PMID:
38468721

View on PubMed View on PMC View Publisher

Journal Information

Journal Title: Front Cardiovasc Med

Detailed journal information not available.

Publication Details

Subject Category: Cardiac & Cardiovascular Systems

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score

2/6

33.3% Transparent

Transparency Indicators

Click on green indicators to view evidence text

Core Indicators

Data Sharing

Code Sharing

COI Disclosure

Evidence found in paper:

"Conflict of interest HY is Speaker and Japanese training faculty member for Abbott Laboratories. TR is Speaker, proctor, and/or preceptor for Abbott, Cardiac Dimensions, Edwards Lifesciences, and NeoChord. RvB is in the Advisory board and speaker for Abbott Vascular, BMS, Edwards Lifesciences, JenaValve, Medtronic, and NeoChord. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

Funding Disclosure

Protocol Registration

Open Access

Paper is freely available to read

Additional Indicators

Replication

Novelty Statement

Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025